Waters Corporation (WAT) - Q3 2008 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 27, 2008. Waters Corporation is a manufacturer of analytical instrument systems, including high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC), mass spectrometry (MS), and thermal analysis instruments. The company operates through two primary divisions: the Waters Division and the TA Division.
Key Financial Metrics
| Metric | Q3 2008 | Q3 2007 | YTD 9M 2008 | YTD 9M 2007 |
|---|---|---|---|---|
| Total Net Sales | $386.3 million | $352.6 million | $1,156.8 million | $1,036.0 million |
| Gross Profit | $227.8 million | $199.0 million | $667.6 million | $586.9 million |
| Gross Margin | 59.0% | 56.4% | 57.7% | 56.6% |
| Operating Income | $98.0 million | $69.2 million | $273.4 million | $219.0 million |
| Net Income | $71.5 million | $53.3 million | $223.1 million | $169.1 million |
| Diluted EPS | $0.71 | $0.52 | $2.21 | $1.65 |
| Cash & Equivalents | $892.6 million | $597.3 million (Dec 2007) | N/A | |
| Total Debt | $1,027.5 million | $884.2 million (Dec 2007) | N/A | |
| Operating Cash Flow (9M) | N/A | $306.0 million | $266.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% in Q3 and 12% year-to-date (YTD), driven by demand in Europe, Asia, and Latin America, as well as a 3% to 5% benefit from foreign currency translation.
- Profitability: Operating income rose 42% in Q3 and 25% YTD. Gross margins expanded due to higher sales volume and favorable currency effects.
- Accounting Adjustments: In Q2 2008, the company corrected prior period errors, resulting in a $16 million tax benefit and a $9 million increase in amortization expense. These adjustments reduced the effective tax rate by 5.6 percentage points for the YTD period.
- Acquisitions: The company acquired VTI Corporation in July 2008 for $3 million, contributing to TA Division growth.
Guidance, Outlook, and Risks
- Debt Repayment: In October 2008 (post-period), the company utilized $572 million in repatriated cash to voluntarily prepay $490 million in debt ($150 million term loan and $340 million revolving credit), reducing leverage and interest rate risk.
- Share Repurchases: The company repurchased $211 million of stock YTD 2008. Approximately $125 million remains authorized under the current program.
- Outlook: Management expects selling and administrative expenses to grow at a slightly lower rate for the remainder of 2008. Inventory levels are elevated in anticipation of Q4 sales.
- Risks: Key risks include global economic disruption affecting credit markets and customer demand, foreign exchange rate fluctuations (70% of sales are outside the U.S.), and reliance on pharmaceutical industry spending.
Investor Verification Checklist
- Debt Structure: Verify the impact of the October 2008 debt prepayments on the balance sheet in the subsequent 10-Q filing.
- Inventory Levels: Monitor inventory trends ($206 million at period end) to ensure they decline as expected in Q4 to avoid write-downs.
- Effective Tax Rate: Assess the sustainability of the 14.1% YTD effective tax rate, which was significantly influenced by a one-time $16 million tax benefit from prior error corrections.
- Currency Exposure: Evaluate the sensitivity of future earnings to foreign exchange rates, given that 70% of sales are international.
- Capital Allocation: Track the remaining $125 million authorized for share repurchases and potential future acquisitions.